Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLI1 | Q01543 | 5/20 | 1.00 |
| ▸ | EWSR1 | Q01844 | 5/20 | 1.00 |
| ▸ | ERG | P11308 | 1/20 | 1.00 |
| ▸ | ETV1 | P50549 | 1/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 0.64 |
| ▸ | MMP9 | P14780 | 5/20 | 0.64 |
| ▸ | MMP8 | P22894 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CBX7 | O95931 | 1/20 | 0.47 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19829782 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19829781 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29399443 | 1.00 | FLI1 (1.00) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL29810794 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679820 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17669251 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL17679823 | 0.91 | FLI1 (0.83) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337311 | 0.89 | FLI1 (0.80) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL19419557 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 | |
| SCHEMBL15337268 | 0.88 | FLI1 (0.78) | FLI1EWSR1ERGETV1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161626-B2 | Uses of indolinone compounds | Oncternal Therapeutics, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3795563-B1 | INDOLINE ANALOGS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-114569606-B | Use of indolinone compounds | 英克特诺治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-3204376-B1 | INDOLINONE COMPOUNDS AND USES THEREOF | ONCTERNAL THERAPEUTICS INC (US) | 2023-04-19 | — | — | EP | disclosed |
| US-20220362211-A1 | USES OF INDOLINONE COMPOUNDS | GEORGETOWN UNIVERSITY | 2022-11-17 | — | — | US | disclosed |
| CN-109219594-B | Indoline analogue and application thereof | 英克特诺治疗公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-114569606-A | Use of indolinone compounds | 英克特诺治疗公司 | 2022-06-03 | — | — | CN | disclosed |
| US-11285132-B2 | Uses of indolinone compounds | Oncternal Therapeutics, Inc. (US) | 2022-03-29 | — | — | US | disclosed |
| CN-109789127-B | Use of indolinone compounds | 英克特诺治疗公司 | 2022-03-25 | — | — | CN | disclosed |
| WO-2014015153-A2 | COMPOSITIONS AND METHODS FOR TREATING EWING'S SARCOMA AND OTHER DISORDERS RELATED TO EWS-FLI1 | STAR BIOTECHNOLOGY, LLC (US) | 2014-01-23 | — | — | WO | disclosed |
| WO-2013155341-A1 | METHODS AND COMPOSITIONS FOR TREATING EWINGS SARCOMA FAMILY OF TUMORS | GEORGETOWN UNIVERSITY (US) | 2013-10-17 | — | — | WO | disclosed |
| US-8232310-B2 | Targeting of EWS-FLI1 as anti-tumor therapy | GEORGETOWN UNIVERSITY (US) | 2012-07-31 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| WO-2008083326-A2 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | GEORGETOWN UNIVERSITY (US) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004179-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
| US-11285132-B2 | Uses of indolinone compounds | MCL1, BCL3, BCL9 | FLI1 8/4885EWSR1 823/4885ERG 311/4885 |
| US-20220362211-A1 | USES OF INDOLINONE COMPOUNDS | MCL1, BCL3, BCL9 | FLI1 8/4885EWSR1 823/4885ERG 311/4885 |
| US-12161626-B2 | Uses of indolinone compounds | MCL1, BCL3, BCL9 | FLI1 8/4885EWSR1 823/4885ERG 311/4885 |
| US-20100167994-A1 | TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY | EWSR1, FLI1, PELI1 | FLI1 2/4885EWSR1 1/4885ERG 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.